echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The Lancet sub-journal: Hengrui Medicine Apatini treats advanced spinal cord tumor mPFS for 18 months.

    The Lancet sub-journal: Hengrui Medicine Apatini treats advanced spinal cord tumor mPFS for 18 months.

    • Last Update: 2020-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, The Lancet Oncology, a sub-issue of The Lancet, published an online study called "The Application of Apatini in Patients with Advanced Spinal Cordoma: A Single-Armed, Single-Center Phase 2 Clinical Study."
    , according to the article, this is the first trial of Apatini's treatment of advanced spinal cord tumor, completed by Professor Xiao Jianru and Professor Yang Cheng of Shanghai Long March Hospital.
    positive results from the study suggest that apatinist may be a new option for treating advanced spinal cord tumors.
    Apatini is a small molecularly targeted drug developed by Hengrui Pharmaceuticals, which inhibits the production of tyrosine kinase by highly selectively competing ATP binding points of VEGFR-2 in cells, thereby inhibiting the production of new blood vessels in tumor tissue, thus achieving anti-tumor purposes.
    the drug was approved in 2014 for use in patients with advanced gastric adenocarcinoma or gastric-esophageal adenocarcinoma.
    is a rare primary malignant bone tumor that originates from the residual spinal cord tissue of the embryo.
    , there is no standard clinical treatment for advanced spinal cord tumor, the occurrence of local recurrence after surgery is about 50%, the transfer rate is about 20%.
    studies have shown that apatinist has good efficacy and controlled adverse reactions to the treatment of solid tumors.
    study, published in The Lancet Oncology, aims to study the safety and anti-tumor activity of apatinists in patients with advanced spina blond tumors.
    study screened 32 patients with advanced spinal cordoma between August 21, 2017 and May 31, 2019, 30 of which were included in the Intent Therapy (ITT) analysis.
    subjects were treated with 500 mg of apatinist once a day or so during the trial until the disease progressed or beedible for toxicity.
    study ends with progress-free lifetime (PFS) and objective mitigation rate (ORR) assessed according to RECIST 1.1 and Choi standards.
    results showed that, according to RECIST 1.1, 1 patient (3.7 percent; 95 percent CI 0 to 11.3) of the 27 patients in the ITT population achieved an objective response, with a medium PFS of 18 months (95 percent CI 3 to 34).
    the Choi standard, 7 patients (25.9%; 8.3 to 43.6) achieved an objective response, with a medium PFS of 18 months (3 to 33).
    addition, the study also found that apatinib has a good effect on spinal cord tumor lung metastasis, can significantly reduce spinal cord tumor lung metastasis.
    the efficacy assessed according to THEIST 1.1 and Choi standards (screenshot source: References.
    the most common level 3 adverse reactions associated with treatment were hypertension (7 out of 29 patients) and proteinuria (2), and no treatment-related level 4 adverse events or treatment-related deaths were observed.
    addition, most patients have significantly relieved their pain after six months of treatment.
    this is the first trial of Apatini's treatment of advanced spinal cord tumors and has shown promising activity and controlled toxicity, according to the article.
    , apatinist may be a new option for treating advanced spinal cord tumors.
    it is worth noting that Hengrui Pharmaceuticals is conducting dozens of clinical trials on apatini.
    according to the drug clinical trial registration and information publicity platform, Apatinistinist registered to carry out up to 44 clinical studies, adaptations include advanced hepatocellular carcinoma, lung cancer, triple-yin breast cancer, small cell lung cancer and so on.
    : apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. Retrieved Sep 8,2020, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.